MedPath

Comparing Naproxen to Sumatriptan for Emergency Headache Patients

Phase 4
Completed
Conditions
Migraine
Tension-type Headache
Primary Headache Disorder
Interventions
Registration Number
NCT00449787
Lead Sponsor
Montefiore Medical Center
Brief Summary

2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment. The goal of this study is to compare two medications, naproxen and sumatriptan, to determine which is better for the treatment of recurrent headache within 24 hours of emergency department discharge.

Detailed Description

Two-thirds of the five million headache patients who present to US emergency departments (ED) annually are suffering an acute exacerbation of a primary headache disorder. Of these acute primary headaches, migraine is the most frequently encountered disease entity in the ED, accounting for 60% of primary headaches, followed by tension-type headaches, which represent 10% of all primary headaches seen in the ED. About ¼ of all acute primary headaches seen in the ED cannot readily be given a specific diagnosis3. Multiple parenteral treatments are used to treat acute primary headaches1, but to date, regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of headache after ED discharge. To date, it is unknown which medication patients should be given when discharged from an ED after treatment for a primary headache. This study will compare two oral headache treatments to determine which one relives pain more effectively.

Specific aims:

1) To determine which of two oral medications is more efficacious for all acute primary headache patients who are discharged from an ED.

Primary hypotheses:

In the 48 hour period following ED treatment for a primary headache, sumatriptan 100mg will relieve pain better than naproxen 500mg, as measured by an 11-point numerical rating scale for pain.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
401
Inclusion Criteria
  • Treated in the emergency department for acute primary headache
Exclusion Criteria
  • Allergy, intolerance, or contra-indication to one of the study medications

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SumatriptanSumatriptan 100 mgSumatriptan 100 mg tablet
NaproxenNaproxenNaproxen 500 mg tablet
Primary Outcome Measures
NameTimeMethod
Numerical Rating ScaleBaseline, two hours

Within 48 hours of ED discharge, participants were allowed to take the investigational medication. At the moment they took the investigational medication, they were asked to record a number from 0 to 10, which represented their headache. 0 signified no pain and 10 signified the worse pain imaginable.

Two hours later, participants were asked again to record their pain on a scale from 0 to 10. The outcome is the change in pain between baseline and two hours and will be a number between 0 and 10. Greater numbes signify greater relief

Secondary Outcome Measures
NameTimeMethod
Headache-related Functional DisabilityBaseline, two hours

This is a recommend outcome in headache research. At the time of the assessment (48 hours after ER discharge), patients are asked to report their current level of functional impairment: severe (unable to do any activities); moderate (able to do a few activities); mild (able to do many but not all activities) or none (able to do all activities). For this analysis, patient's answers were dichotomized into some impairment or no impairment.

Patient Satisfaction48 hours after ER discharge

At the 48 hour assessment, patients were asked, "The next time you go to an emergency room with a headache, do you want to receive the same medication". This outcome tabulates the number of affirmative responses.

Trial Locations

Locations (2)

Columbia University Medical Center

🇺🇸

New York, New York, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath